Report Package: Claudin 18.2-Targeted Immunotherapeutics

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Claudin18.2 is a highly specific cell surface molecule that is often abnormally expressed in primary gastric cancer as well as in other solid tumors such as pancreatic and esophageal cancers. Claudin 18.2 has gained considerable interest as a cancer target for development of claudin 18.2-targeted immunotherapy candidates. Apart from providing promise as an effective therapy, it also allows the application of a wide variety of drug modalities to generate development candidates. After approval in Japan of the first immunotherapy against claudin 18.2, the pipeline is packed with at least 44 candidates in the clinical stage and ten in the non-clinical or IND/CTA development stage.

This report package includes a full report of August 2023 analyzing in depth the landscape of  claudin 18.2-targeted immunotherapy regarding stakeholders, drug modalities, pipeline and business opportunities from an industry perspective. The competitor analysis of April 2024 updates the competitive field of CLDN18.2-targeted immunotherapy candidates.

The original reports were published in August 2023 and April 2024, respectively:

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

(with a 20% discount on the original full report)

and

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Detailed report descriptions and tables of content of the reports can be found on the respective product page.